Moderna Inc (MRNA) Stock Price and Forecast: Moderna works on Omicron booster
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- Moderna shares rally as Omicron booster jab becomes possible.
- MRNA stock still struggling for momentum since last earnings report.
- Is covid coming to a close and can Moderna (MRNA) replace this income stream?
Moderna shares jumped on Monday as the vaccine maker says it is working on a covid booster shot targeting the Omicron variant. This and an increase to earnings guidance were welcomed by investors. The shares closed 9% higher at $233.70.
Moderna (MRNA) stock news
Moderna shares have been struggling since the last earnings report in November. MRNA price broke below $300, and it took the emergence of Omicron to reverse that trend. However, as more and more evidence mounted that Omicron appears less severe, Moderna has resumed the downtrend with the occasional spike as witnessed yesterday.
The big question surrounding investment in this one is how to replace the massive revenue stream that is covid vaccination. We are assuming this covid winter is the last one. Perhaps vaccinations will be needed next year, but it is highly unlikely to be anywhere near the extent of the current take-up globally.
How will they replace that income? A flu vaccine is a possibility or treatments aimed at other diseases and conditions. MRNA vaccines may target other diseases, but in reality this pandemic is hopefully a once-in-a-century event. Pharma stocks go back then to being what they often are, speculative development pipelines with investors needing to carefully watch upcoming pipelines and put a probability on the relative success or failure of each potential treatment. You can see Moderna's pipeline here.
Moderna (MRNA) stock forecast
Monday's move looks impressive, but on the chart below it has failed to dent the downtrend. While a guidance upgrade is always welcome and strong vaccine sales as well, the trend is still bearish in our view. Two key pieces of evidence support our view.
First, MRNA has set a lower low than the post-earnings slump. Secondly, Monday's spike has not yet resulted in a higher high. Breaking $260 will change this and make the short-term view bullish. That will then bring a big test of resistance at the big spike from December at $321. Support at $188.41 remains the target otherwise and then onto $157.
Moderna (MRNA) chart, daily
Like this article? Help us with some feedback by answering this survey:
- Moderna shares rally as Omicron booster jab becomes possible.
- MRNA stock still struggling for momentum since last earnings report.
- Is covid coming to a close and can Moderna (MRNA) replace this income stream?
Moderna shares jumped on Monday as the vaccine maker says it is working on a covid booster shot targeting the Omicron variant. This and an increase to earnings guidance were welcomed by investors. The shares closed 9% higher at $233.70.
Moderna (MRNA) stock news
Moderna shares have been struggling since the last earnings report in November. MRNA price broke below $300, and it took the emergence of Omicron to reverse that trend. However, as more and more evidence mounted that Omicron appears less severe, Moderna has resumed the downtrend with the occasional spike as witnessed yesterday.
The big question surrounding investment in this one is how to replace the massive revenue stream that is covid vaccination. We are assuming this covid winter is the last one. Perhaps vaccinations will be needed next year, but it is highly unlikely to be anywhere near the extent of the current take-up globally.
How will they replace that income? A flu vaccine is a possibility or treatments aimed at other diseases and conditions. MRNA vaccines may target other diseases, but in reality this pandemic is hopefully a once-in-a-century event. Pharma stocks go back then to being what they often are, speculative development pipelines with investors needing to carefully watch upcoming pipelines and put a probability on the relative success or failure of each potential treatment. You can see Moderna's pipeline here.
Moderna (MRNA) stock forecast
Monday's move looks impressive, but on the chart below it has failed to dent the downtrend. While a guidance upgrade is always welcome and strong vaccine sales as well, the trend is still bearish in our view. Two key pieces of evidence support our view.
First, MRNA has set a lower low than the post-earnings slump. Secondly, Monday's spike has not yet resulted in a higher high. Breaking $260 will change this and make the short-term view bullish. That will then bring a big test of resistance at the big spike from December at $321. Support at $188.41 remains the target otherwise and then onto $157.
Moderna (MRNA) chart, daily
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.